Clinical Professor Michael Boyer AM

Clinical Professor
Medicine, Central Clinical School

C39 - Royal Prince Alfred Hospital
The University of Sydney
NSW 2006 Australia

T: +61 2 8514 0922
F: +61 2 95157404

W: Related website
Curriculum vitae


Lung cancer; Head and neck cancer

International links

Singapore. (Cancer Therapeutics Research Group) Director of CTRG.


2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008


  • Yip, P., Cooper, W., Kohonen-Corish, M., Lin, B., McCaughan, B., Boyer, M., Kench, J., Horvath, L. (2014), Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. Journal of Clinical Pathology. 67(4), 333-340. [Abstract]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Mallesara, G., Gurney, H., Clark, S., Swarbrick, A., Daly, R., Horvath, L. (2014), Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer. 110(10), 2462-2471. [Abstract]


  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Boyer, M., Stockler, M. (2013), A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer. 81(3), 422-427. [Abstract]
  • Sequist, L., Yang, J., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S., Orlov, S., Tsai, C., Boyer, M., Su, W., Bennouna, J., Kato, T., Gorbunova, V., Lee, K., Shah, R., Massey, D., Zazulina, V., Shahidi, M., Schuler, M. (2013), Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology. 31(27), 3327-3334. [Abstract]
  • Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., Kohonen-Corish, M., Fox, S., Cooper, W., Solomon, B. (2013), Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology. 26(12), 1545-1553. [Abstract]
  • Coupe, N., Cox, K., Clark, K., Boyer, M., Stockler, M. (2013), Outcomes of Permanent Peritoneal Ports for the Management of Recurrent Malignant Ascites. Journal of Palliative Medicine. 16(8), 938-940. [Abstract]
  • McCaughan, G., Blinman, P., Boyer, M., Stockler, M. (2013), Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small cell lung cancer. Internal Medicine Journal. 43(4), 424-429. [Abstract]
  • Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013), Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology. 8(4), 408-414. [Abstract]
  • Spina, R., Chu, S., Chatfield, M., Chen, J., Tin, M., Boyer, M. (2013), Outcomes of Chemoradiation for Patients with Locally Advanced Non-Small-Cell Lung Cancer. Internal Medicine Journal. 43(7), 790-797. [Abstract]
  • Honeyball, F., Boyer, M., van Zandwijk, N., Kao, S. (2013), Malignant pleural mesothelioma. Cancer Forum. 37(2), 181-185.


  • Yeo, W., Chung, H., Chan, S., Wang, L., Lim, R., Picus, J., Boyer, M., Mo, F., Koh, J., Rha, S., Hui, E., Jeung, H., Roh, J., Yu, S., To, K., Tao, Q., Ma, B., Chan, A., Tong, J., Erlichman, C., Chan, A., Goh, B. (2012), Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Journal of Clinical Oncology. 30(27), 3361-3367. [Abstract]
  • Ramalingam, S., Blackhall, F., Krzakowski, M., Barrios, C., Park, K., Bover, I., Seog Heo, D., Rosell, R., Talbot, D., Frank, R., Letrent, S., Ruiz-Garcia, A., Taylor, I., Liang, J., Campbell, A., O'Connell, J., Boyer, M. (2012), Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(27), 3337-3344. [Abstract]
  • Sundaresan, P., Hruby, G., Hamilton, A., Hong, A., Boyer, M., Chatfield, M., Thompson, J. (2012), Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. Clinical Oncology. 24(9), e131-e136. [Abstract]
  • Boyer, M., Horwood, K., Pavlakis, N., DE Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012), Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology. 8(3), 248-254. [Abstract]
  • Kim, G., Mahoney, M., Szydlo, D., Mok, T., Marshke, R., Holen, K., Picus, J., Boyer, M., Pitot, H., Rubin, J., Philip, P., Nowak, A., Wright, J., Erlichman, C. (2012), An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investigational New Drugs. 30(1), 387-394. [Abstract]
  • Yip, P., Barnes, D., McCaughan, B., Boyer, M. (2012), Diagnosis and treatment of lung cancer: A focus on the GP's role. Medicine Today. 13(2), 30-36.
  • Dhillon, H., van der Ploeg, H., Bell, M., Boyer, M., Clarke, S., Vardy, J. (2012), The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol. BMC Cancer. 12, 572. [Abstract]


  • Vansteenkiste, J., Solomon, B., Boyer, M., Wolf, J., Miller, N., Di Scala, L., Pylvaenaeinen, I., Petrovic, K., Dimitrijevic, S., Anrys, B., Laack, E. (2011), Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 6(12), 2120-9. [Abstract]
  • Hirsh, V., Paz-Ares, L., Boyer, M., Rosell, R., Middleton, G., Eberhardt, W., Szczesna, A., Reiterer, P., Saleh, M., Arrieta, O., Bajetta, E., Webb, R., Raats, J., Benner, R., Fowst, C., Meech, S., Readett, D., Schiller, J. (2011), Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(19), 2667-74. [Abstract]
  • Cooper, W., O'toole, S., Boyer, M., Horvath, L., Mahar, A. (2011), What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology. 43(2), 103-115. [Abstract]
  • Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011), A randomised crossover trial comparing inpatient and outpatient administration of high dose cisplatin. Internal medicine journal. (2). [Abstract]
  • Yan, T., Cao, C., Boyer, M., Tin, M., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2011), Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. Annals of Thoracic and Cardiovascular Surgery. 17(3), 243-249. [Abstract]


  • Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010), High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research. 16(23), 5805-5813. [Abstract]
  • Moore, M., Stockler, M., Lim, R., Mok, T., Millward, M., Boyer, M. (2010), A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer chemotherapy and pharmacology. 66(5), 845-50. [Abstract]
  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Craft, P., Boland, A., Simes, R., Toner, G. (2010), Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute. 102(16), 1253-62. [Abstract]
  • Kao, S., McCaughan, B., Muljono, A., Boyer, M. (2010), A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed. Journal of Thoracic Oncology. 5(3), 405-406. [Abstract]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010), Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer. Journal of the Society for Integrative Oncology. 8(2), 56-64. [Abstract]


  • Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009), Reply to A.D. Sasse et al. Journal of Clinical Oncology. 27(35), e254. [Abstract]
  • Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., Sutherland, R., Henshall, S., Horvath, L. (2009), Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research. 69(19), 7696-7703. [Abstract]
  • Yan, T., Boyer, M., Tin, M., Wong, D., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009), Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. The Journal of Thoracic and Cardiovascular Surgery. 138(3), 619-624. [Abstract]
  • Tattersall, M., Dear, R., Jansen, J., Shepherd, H., J Devine, R., G Horvath, L., Boyer, M. (2009), Second opinions in oncology: the experiences of patients attending the Sydney Cancer Centre. Medical Journal of Australia. 191(4), 209-212. [Abstract]
  • Pezaro, C., Rosenthal, M., Gurney, H., Davis, I., Underhill, C., Boyer, M., Kotasek, D., Solomon, B., Toner, G. (2009), An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American journal of clinical oncology. 32(4), 338-41. [Abstract]
  • Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009), Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(20), 3277-83. [Abstract]
  • Simonella, L., O'Connell, D., Vinod, S., Delaney, G., Boyer, M., Esmaili, N., Hensley, M., Goldsbury, D., Supramaniam, R., Hui, A., Armstrong, B. (2009), No improvement in lung cancer care: The management of lung cancer in 1996 and 2002 in New South Wales. Internal medicine journal. 39(0), 453-8. [Abstract]
  • Yan, T., Boyer, M., Tin, M., Sim, J., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009), Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. The Annals of Thoracic Surgery. 87(5), 1552-1556. [Abstract]
  • Martin, R., Fulham, M., Shannon, K., Hughes, C., Gao, K., Milross, C., Tin, M., Jackson, M., Clifford, A., Boyer, M., O'Brien, C. (2009), Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. Head & neck. 31(0), 244-50. [Abstract]
  • Yan, T., Tin, M., Boyer, M., McLean, J., Bannon, P., McCaughan, B. (2009), Treatment Failure after Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. Journal of Thoracic Disease. 1(1), 23-28.
  • Vardy, J., Dadasovich, R., Beale, P., Boyer, M., Clarke, S. (2009), Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC cancer. 9(1), 130. [Abstract]


  • Vinod, S., O'Connell, D., Simonella, L., Delaney, G., Boyer, M., Peters, M., Miller, D., Supramaniam, R., McCawley, L., Armstrong, B. (2008), Gaps in optimal care for lung cancer. Journal of Thoracic Oncology. 3(8), 871-879. [Abstract]
  • Kenny, P., King, M., Viney, R., Boyer, M., Pollicino, C., McLean, J., Fulham, M., McCaughan, B. (2008), Quality of life and survival in the 2 years after surgery for non small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(2), 233-241. [Abstract]